Researchers evaluated the antibody response among 84 pregnant women, 31 women who were breastfeeding and 16 nonpregnant women who received Pfizer or Moderna’s mRNA vaccines. Participants were sampled after their first or second doses, with a subset sampled after each of the doses.
Pregnant and breastfeeding women had fewer antibodies than other women of the same age after their first dose, the findings showed. Those antibodies were also less effective at kickstarting other parts of the immune system to ward off the virus.
Two to six weeks after the second dose, however, pregnant and breastfeeding women had about the same level of antibodies of their nonpregnant counterparts.
“The authors found that two doses of vaccine were required for pregnant or lactating women to achieve immune responses comparable to that of nonpregnant women,” the Oct. 19 study said.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
